Whole Blood Metabolomics in Aging Research by Hiroshi Kondoh et al.
Whole Blood Metabolomics in Aging Research














Creative Commons Attribution 4.0 International(https://creativecommons.org/licenses/by/4.0/)
 International Journal of 
Molecular Sciences
Review
Whole Blood Metabolomics in Aging Research
Hiroshi Kondoh 1,*, Masahiro Kameda 1 and Mitsuhiro Yanagida 2


Citation: Kondoh, H.; Kameda, M.;
Yanagida, M. Whole Blood
Metabolomics in Aging Research. Int.
J. Mol. Sci. 2021, 22, 175. https://
dx.doi.org/10.3390/ijms22010175
Received: 10 December 2020
Accepted: 25 December 2020
Published: 26 December 2020
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional claims
in published maps and institutional
affiliations.
Copyright: © 2020 by the authors. Li-
censee MDPI, Basel, Switzerland. This
article is an open access article distributed
under the terms and conditions of the
Creative Commons Attribution (CC BY)
license (https://creativecommons.org/
licenses/by/4.0/).
1 Geriatric Unit, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan;
mkameda@kuhp.kyoto-u.ac.jp
2 G0 Cell Unit, Okinawa Institute of Science and Technology Graduate University (OIST),
Okinawa 904-0495, Japan; myanagid@gmail.com
* Correspondence: hkondoh@kuhp.kyoto-u.ac.jp; Tel./Fax: +81-75-751-3465
Abstract: Diversity is observed in the wave of global aging because it is a complex biological
process exhibiting individual variability. To assess aging physiologically, markers for biological aging
are required in addition to the calendar age. From a metabolic perspective, the aging hypothesis
includes the mitochondrial hypothesis and the calorie restriction (CR) hypothesis. In experimental
models, several compounds or metabolites exert similar lifespan-extending effects, like CR. However,
little is known about whether these metabolic modulations are applicable to human longevity, as
human aging is greatly affected by a variety of factors, including lifestyle, genetic or epigenetic
factors, exposure to stress, diet, and social environment. A comprehensive analysis of the human
blood metabolome captures complex changes with individual differences. Moreover, a non-targeted
analysis of the whole blood metabolome discloses unexpected aspects of human biology. By using
such approaches, markers for aging or aging-relevant conditions were identified. This information
should prove valuable for future diagnosis or clinical interventions in diseases relevant to aging.
Keywords: aging; metabolites; frailty; fasting; antioxidant; metabolomics; whole blood
1. Diversity of Human Aging Exposes the Limits of Calendar Age
Currently, Japan is the only country in the world with a societal aging rate (% of
population over 65 years old) exceeding 30% (global average = 12.38%) [1,2]. However,
a wave of global aging is steadily approaching, and the global average is expected to reach
23.4% by around 2050 [1]. Indeed, many European countries, China, South Korea, Thailand,
Singapore, Iran, Chile, Canada, and others will reach aging rates of more than 25%, while
Japan is expected to exceed 42.5% by that time [1].
One of the major causes of this global aging is improved health of the elderly especially
due to medical progress. However, the causes of “aging” change through time. As one
leading cause of death is overcome, another takes its place. For example, immediately after
World War II, antibiotics helped to eliminate many infectious diseases, thereby extending
life expectancy, while in the 1960s, cerebral hemorrhage was a major reason that elderly
people became bedridden [3,4]. Now, we observe greater “diversity of aging” in countries
with a high proportion of elderly people, including Japan. As the number of healthy
elderly people increases, the number of bedridden patients and people who need long-term
nursing care increases as well.
Because “diversity of aging” reflects individual variability, clinical symptoms among
the elderly are also diverse. For example, atherosclerosis is a well-known disease that
accompanies aging. Endothelial thickening of the carotid artery and increased vascular
pulse wave velocity are indicators of arteriosclerosis, which predicts vascular age [5].
Average values for such parameters in the elderly are worse than those of young people.
Careful observation reveals that these indicators show uniformly low values among the
young, while values measured in the elderly range largely from low to high [5]. It is true
that there are some older people who have better indicator values than younger people.
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These findings demonstrate that “aging” is multi-faceted and complex, and that variability
is characteristic of aging.
Calendar age has conventionally been used as an indicator of human aging. According
to calendar age, the elderly are classified into four groups: Early elderly (65 to 74 years
old), late elderly (over 75 years old), super-elderly (over 90 years old), and centenarians,
people over 100 years of age. This definition, based on calendar age, was proposed by the
United Nations in 1956. However, as we are now facing global aging of the population
and diversification of the elderly, redefinition of “elderly” itself is becoming necessary
(proposal of the Japanese Geriatrics Society in 2017).
2. The Aging Hypothesis Relative to Metabolic Profiles
In addition to calendar age, the importance of “biological age” has also been proposed,
mainly based on findings in basic aging research. For example, “telomeres” are known as
“aging clocks” in replicative senescence. Other attempts to explain metabolic aspects of
“aging” include the “oxidative stress hypothesis” and the “calorie restriction hypothesis”
(Figure 1).
Int. J. ol. i. , , x FOR PEER REVIEW 2 of 13 
 
 
se findings demonstrate that “aging” is multi-fac ted and complex, and that variabil-
ity is characteristic of a ing. 
l r age has conventionally b en used as an indicator of human aging. Accord-
ing to calendar age, the lderly are classified int  four groups: Early elderly (65 to 74 years 
  l     l , l     l ,  t  
l  r  rs f .  fi iti ,   l r , s r se   t e 
   .      faci  gl l a i  of the populatio  
 fi    l , re efi iti  of “el erl  itself is beco i  necess r  
( s l f t e Ja a ese eriatrics Society in 2017). 
2. The Aging Hypothesis Relative to etabolic Profiles 
In addition to calendar age, the importance of “biological age” has also been pro-
posed, mainly based on findings in basic aging research. For example, “telomeres” are 
known as “aging clocks” in replicative senescence. Other attempts to explain metabolic 
aspects of “aging” include the “oxidative stress hypothesis” and the “calorie restriction 
hypothesis” (Figure 1). 
 
Figure 1. The aging hypothesis relative to metabolism. Earlier, “the oxidative damage hypothesis” or “mitochondrial aging 
hypothesis” was proposed by Harman, as oxidative stress reduces organismal lifespan. Calorie restriction (CR) or inter-
mittent fasting (IF) effectively extends lifespans of experimental models. During CR, several signal modules, including 
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of these signals is FOXO transcriptional factor, which activates radical scavengers. However, recent findings on 
mitohormisis challenge the mitochondrial aging hypothesis. Moreover, little is known about the effect of CR or fasting on 
human longevity. Some of the metabolites described in this review (red color) are known to interact with the signal mol-
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The former is one of the oldest aging hypotheses, proposed by Harman (1956) [6].
During his search for chemical inducers of DNA mutations, he became aware of the highly
reactive properties of “free radicals.” Damage to large molecules caused by free radicals
is known as “oxidative stress.” Telomeric DNA is also impaired by oxidative stress [7].
Oxidative stress was proposed as a cause of aging by Harman and more recently as a
factor in chronic inflammation. Indeed, lifespan extension in experimental models was
promoted by ectopic expression of “radical scavengers”, such as catalase and super oxide
dismutase (SOD) [8,9]. In addition, over 90% of oxidative stress has been attributed to
mitochondria [10]. The “Mitochondrial Aging Hypothesis” proposed by Harman (1972)
suggested that oxidative stress greatly increases biological age [11]. Consistently, the genetic
manipulation to extend the lifespan is known to be accompanied with the increase of
antioxidants; for example, glutathione has been elevated in super Arf/p53 mice, a longevity
model [12].
When calorie intake is reduced by 20–30%, lifespan is extended by 20% or more in
many model organisms, such as mice, flies, fish, spiders, etc. [13,14]. Calorie restriction
(CR) activates and modulates several signal responses, such as sirtuin, AMPK kinase,
Tor kinase, and FOXO transcription factor [15–20]. Targets of FOXO transcription fac-
tor include a group of radical scavenger genes. Consistently, during CR, reduction of
oxidative stress is observed, indicating the role of oxidative stress in the “calorie restric-
tion hypothesis” [21,22]. A recent report suggested that the modulation of FOXO via
peptide intervention induces elimination of senescent cells in vivo, followed by healthy
lifespan [23].
Interestingly, metabolites modulating these signaling pathways are effective both
for extension of organismal lifespan in experimental models and for treatment of human
diseases of aging: Resveratrol (activator of sirtuins) against obesity, rapamycin (inhibitor
for Tor kinase) as an anti-cancer drug or immunosuppressor, and metformin (activator
for AMPK) in diabetic therapy [17,24–26]. NAD+ also activates sirtuins, while lifespan is
extended by adipose-tissue-specific expression of Nampt, which mediates NAD+ biosynthe-
sis [27]. Moreover, nicotinamide mononucleotide (NMN), a precursor of NAD+, alleviates
age-related functional decline in rodents [28]. However, as ectopic expression of FOXO
compromises metabolic regulation in mice, it is not clear whether modulation of FOXO
would be efficacious in clinical applications [29,30].
Moreover, the mitochondrial aging hypothesis has been challenged since about 2005.
Recent genetic studies suggest that lifespan in Caenorhabditis and Drosophila are extended by
partial inactivation of mitochondrial functions, such as mitochondrial SOD, mitochondrial
complex protein, and mitochondrial ribosomal proteins [31–33]. Moreover, it was observed
that very limited but defined overload of “mitochondrial oxidative stress” (“mitohorme-
sis” [34]) extended lifespan in nematodes.
These conflicting findings on oxidative stress and longevity cannot be overlooked.
In human clinical trials, supplementation with the antioxidants, beta-carotene, vitamin
A, or vitamin E reduced mortality [35,36]. Regarding the “calorie restriction hypothesis”,
long-term clinical studies by CR intervention in humans are very difficult, except for obesity
or diabetes, as some epidemiological studies suggest that slightly overweight people live
longer [37]. Compared to that in model organisms, human aging research may require
another approach, in part due to its variability and complexity.
Other than CR, supplementations of several metabolites are under investigation, for
example NMN [38], as intervention approach against human aging. The combination
of exercise and supplementation for branched-chain amino acids strengthens lower limb
muscles in physical frailty [39]. Thus, metabolites could be a promising strategy for
intervention against aging.
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3. Metabolomic Approach for Human Whole Blood
Metabolites are small organic compounds, generated by the metabolic activity of living
organisms, from bacteria to humans. The metabolome comprises numerous metabolites
that may be quantified with liquid chromatography–mass spectrometer (LC-MS). Analysis
of the metabolome (metabolomics) is developing as a powerful and useful tool, not only to
search for diagnostic metabolites or biomarkers, but also to provide valuable information
about metabolic profiles of tissues, cells, media, urine, and blood, in health and disease.
Among other things, human blood is convenient and useful to analyze, because
it reflects in vivo physiological states influenced by genetics, epigenetics, health, and
lifestyle [40,41]. Thus, metabolomics of human blood can provide comprehensive informa-
tion on metabolic mechanisms of physiological responses, health, aging, and diseases, and
of biological effects of drugs, nutrients, and environmental stressors [42–46].
Blood comprises cellular and non-cellular components: Red blood cells (RBCs), white
blood cells (WBCs), platelets, and plasma. Many studies on blood have been conducted
on plasma or serum, the non-cellular component [47,48]. One reason is the difficulty in
handling cell-derived metabolites so as to promote their stability [49].
We pursued and established our own method for analyzing whole blood, plasma, and
RBCs. The whole blood metabolome includes about 130 metabolites, comprising over 14
subgroups (nucleotides, nucleosides, nucleobases, vitamins and coenzymes, nucleotide-
sugar derivatives, sugar phosphates, sugar derivatives, choline and ethanolamine deriva-
tives, organic acids, anti-oxidants, amino acids, methylated compounds, acetylated com-
pounds, carnitines, etc.) [50–53]. These reflect cellular metabolism (energy production,
DNA and RNA synthesis, lipid metabolism, mitochondrial respiration, redox homeostasis,
protein synthesis, and so on). Hence, levels of these compounds are influenced or regulated
by various activities of tissues, activation or inactivation, secretion or absorption, regenera-
tion or degradation, contraction or relaxation, digestion or condensation, accumulation,
or excretion, etc.
Among the ~130 metabolites assessed by whole blood metabolomics, 50–60 are en-
riched in RBCs [52,53]. Individual differences in each metabolite were also evaluated [53].
Based on the coefficient of variation (CV: SD divided by the mean), metabolites are clas-
sified into two subgroups: Those that are less variable (CV < 0.4) and others with large
variability (CV > 0.4 or higher). The former comprise many essential metabolites (ATP,
glutathione, phospho-sugars, etc), while the latter include dietary compounds such as caf-
feine, carnosine, ergothioneine, 4-aminobenzoate, and others [53]. Thus, our metabolomic
approach to whole blood comprehensively captures complex changes with individual
differences, suitable for human aging research. Indeed, whole blood metabolomics have
revealed metabolites that serve as biomarkers relevant to aging, fasting, and frailty [53–56].
4. Whole Blood Metabolites for Aging and Fasting Markers
4.1. Metabolites for Aging
While targeted metabolomic analysis has identified aging-relevant
compounds [46,47,57,58], a comparative, non-targeted analysis of the whole blood
metabolome was carried out to compare healthy young and elderly people [53]. Among the
126 metabolites identified, there were statistically significant differences in 14 metabolites
(11%) between young people (29 ± 4 years old) and elderly (81 ± 7 years old), which can
be regarded as aging markers. Six of them are RBC-enriched, suggesting that whole blood
metabolomics is important for human aging research.
Nine of the 14 metabolites decreased in the elderly, while five of them increased
(Table 1). The former include 1,5-anhydroglucitol (1,5-AG), acetyl-carnosine, carnosine,
ophthalmic acid (OA), leucine, isoleucine, nicotinamide adenine dinucleotide (NAD+),
nicotinamide adenine dinucleotide phosphate (NADP+), and UDP-acetyl-glucosamine,
while the latter comprise citrulline, pantothenate, dimethyl-guanosine, N-acetyl-arginine,
and N6-acetyl-lysine.
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Table 1. Fourteen metabolites for aging overlap with those for fasting and frailty.
Metabolites Abundance Levels in Elderly Levels in Fasting Levels in Frailty Fraction Role in Blood
1,5-anhydroglucitol
(1,5-AG) H-M ↓ ↓ RBC Antioxidant
acetyl-carnosine L ↓ ↓ Plasma Antioxidant
carnosine L ↓ ↑ Plasma Antioxidant
ophthalmic acid (OA) H-M ↓ ↑ ↓ RBC Antioxidant
leucine H-M ↓ ↑ ↓ Plasma Musclemaintenance
isoleucine H-M ↓ ↑ ↓ Plasma Musclemaintenance
NAD+ H-M ↓ RBC Redox homeostasis
NADP+ H-M ↓ RBC Redox homeostasis
UDP-acetyl-glucosamine L ↓ RBC Sugar nucleotide
citrulline H-M ↑ Plasma Urea cycle
pantothenate H-M ↑ ↑ RBC Precursor of CoA
dimethyl-guanosine L ↑ Plasma Urine compound
N-acetyl-arginine L ↑ Plasma Urea cycle
N6-acetyl-lysine L ↑ Plasma Acetylated aminoacid
Whole blood metabolomics reported 14 metabolites as aging markers. Of these, six metabolites were enriched in RBCs (red). The upper
panel (blue box) shows nine metabolites that decrease in the elderly, while the lower panel (grey boxes) list metabolites that increase in the
elderly. Notice that several compounds overlap with markers for fasting or frailty. Properties of metabolites are added. Metabolites with
peak area > 107 AU are shown as H-M (High to Medium) in red, and metabolites with peak area <107 AU are shown as L (Low) in blue.
The 1-deoxy form of glucose, 1,5-AG, is derived from many foods. Circulating 1,5-
AG is excreted from renal glomeruli, but reabsorbed through renal proximal tubules.
As glucose is a competitive inhibitor of reabsorption of 1,5-AG, diabetic patients with high
blood glucose levels show lower 1,5-AG levels. Thus, 1,5-AG is a known diabetes marker.
However, levels of HbA1c and serum glucose, other diabetic parameters, are normal in both
healthy young and elderly in this study; hence, it is possible that re-absorption of 1,5-AG in
the kidneys is reduced with aging even in healthy people [53]. It is noteworthy that 1,5-AG
also plays a role in oxidative defense. Carnosine and acetyl-carnosine are dipeptides with
antioxidant properties, which are abundant in muscles and neurons [59,60].
OA is a tripeptide analog of glutathione, and L-γ-glutamyl-L-α-aminobutyrylglycine
is synthesized by some of the same enzymes (glutathione synthase) utilized for glutathione
production. Because glutathione is one of the most abundant antioxidative compounds
in cells, OA is known as an oxidative stress marker [61]. NAD+ and NADP+ are coen-
zymes involved in various redox reactions. Leucine and isoleucine are essential amino
acids involved in maintenance of skeletal muscle [62]. Recent blood metabolomics study
consistently identified reduction of essential amino acids in elderlies [63]. UDP-acetyl-
glucosamine is a substrate for glycosyl-based modifications and is involved in synthesis of
proteoglycans and glycolipids [64,65].
Among metabolites that increase in the elderly, citrulline is synthesized in the urea
cycle, and is involved in excretion of nitrogen. Dimethyl-guanosine and N-acetyl-arginine
are also related to nitrogen metabolism [66,67]. These results suggest that urinary discharge
of nitrogen-related metabolites is reduced in the elderly. Pantothenate is a precursor of
coenzyme CoA, involved in the TCA cycle and β-oxidation.
Correlation analysis among these 14 aging compounds suggests strong correlations
among metabolites with declining values in elderly, and also among those that increase in
the elderly. However, interestingly, there was no negative (reverse) correlation between
these two subgroups, indicating at least two distinct subgroups for aging metabolites.
Collectively, these 14 metabolites include antioxidants, nitrogen, and muscle- or
kidney-related metabolites, reflecting a decline or impairment in specific physiological
functions in the elderly. Such functional declines have been assumed in aging, but have
rarely been discussed as conventional indicators. Thus, whole blood metabolomics identi-
fied both undesirable accumulations and deficiencies of metabolites in aging.
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4.2. Fasting Responses; Energy Substitution
As mentioned above, the positive impact of CR on organismal longevity has been well
established in experimental models. Moreover, recent reports suggest that intermittent
fasting, a cycle of fasting and feeding, enables C. elegans to live about 50% longer than
conspecifics on a normal diet [68]. Thus, CR and intermittent fasting have overlapping roles
in prolongation of lifespan. However, verification of the “calorie restriction hypothesis” in
healthy, non-obese humans is rather difficult.
While little is known about the link between fasting and aging in humans, it is well
known that humans can withstand 30–40 days of fasting if dehydration is avoided [55],
in sharp contrast to the vulnerability of mice to hunger (average survival of only several
days of starvation). For example, Gandhi experienced hunger strikes of up to 21 days, 14
times or more in his lifetime as a form of political protest [69].
Historically, research on fasting physiology has focused particularly on energy substi-
tution [70–73]. Glucose normally constitutes the major fuel source under non-fasting
conditions, but during fasting, glycogen stores are rapidly exhausted in an effort to
maintain minimum glucose levels in the blood. After depletion of glycogen storage,
in addition to gluconeogenesis, fasting forces the human body to utilize various non-
carbohydrate metabolites, such as lipids and branched-chain amino acids (BCAAs) as
energy sources [70,73]. Hormonal changes stimulate lipolysis in white adipose tissue
(WAT) and liver. First, 3-hydroxybutyrate (3-HB) increases 30 to 60-fold and is converted
into acetyl-CoA in the brain or other tissues as an alternative energy source [70]. Second, el-
evated acylcarnitines during fasting are essential for lipid transport into mitochondria [74].
Third, increased concentrations of branched-chain amino acids (BCAAs), mainly released
from muscle, are also utilized in the mitochondrial TCA cycle or in liver lipogenesis [75].
Thus, elevation of butyrates, BCAAs, and acylcarnitines in circulating blood (quantified by
targeted metabolomics or other techniques) serve as indicators of fasting.
Additionally, non-targeted, comprehensive analysis of blood metabolites during pro-
longed fasting was performed to gain insights into its health effects [54]. Therefore, we con-
ducted an exhaustive analysis of nearly 130 metabolites from blood of four healthy young
people for 58 h of starvation. As a result, this study revealed that more than one-third of
metabolites increased, indicating much greater metabolic activation during fasting than
expected. Among 44 increased metabolites, well-known fasting markers figure prominently
(ketone bodies, carnitines, and BCAAs), consistent with previous findings [70,73,74].
4.3. Fasting Responses and Novel Fasting Markers
In addition, several novel aspects of fasting were discovered involving (1) TCA cycle
metabolites, (2) antioxidants, and (3) signaling molecules (Figure 2). First, an increase in
TCA cycle metabolites reflects activation of mitochondrial function throughout the body
during starvation, since red blood cells are not equipped with mitochondria. Increases of
well-established fasting metabolites, ketone bodies, carnitines, and BCAAs, also support
mitochondrial activity during fasting. Second, an increase in antioxidant compounds
was also observed, in addition to urate, xanthine, carnosine, OA, and ergothioneine (ET).
Urate is one of the most abundant antioxidants in blood [76], the precursor of which
is xanthine. ET is abundant in mushrooms and fungi. In yeast, ET also increases in
a low-glucose environment [77]. Additionally, four metabolites (6-phosphogluconate,
glucose-6-phosphate, pentose phosphate, and sedoheptulose-7-phosphate) generated via
the pentose phosphate pathway (PPP) increased in plasma, but not in RBCs during fasting.
Activation of the PPP produces NADPH, which is essential for redox control [78]. As sugar
phosphate compounds in blood are enriched in RBCs, PPP metabolite increases only in
plasma suggest that responses in tissues are largely responsible for these altered profiles
during fasting. Collectively, one of the most significant metabolic changes during starvation
is antioxidant enhancement.
Int. J. Mol. Sci. 2021, 22, 175 7 of 13Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 7 of 13  
 
 
Figure 2. Whole blood metabolomics detect markers for aging and fasting. Overlapping, but dis-
tinct markers for aging and fasting are identified by non-targeted, comprehensive metabolomic 
analysis of human whole blood. Various antioxidative metabolites are included in the list of aging 
and fasting markers. In addition to known energy substitutions, unexpected aspects of fasting 
(antioxidants, mitochondrial activation, and signal reprogramming) were revealed. In response to 
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lites increased during fasting did not overlap with the compounds increased in elderly, except 
pantothenate. Please notice that four metabolites decreased in elderly (OA, carnosine, leucine, and 
isoleucine) were increased during fasting, indicating the possible anti-aging effect of fasting. 
BCAA; branched chain amino acid, ET; ergothioneine, 1,5-AG; 1,5-anhydroglucitol (1,5-AG), OA; 
ophthalmic acid, PPP; pentose phosphate pathway. 
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vokes global remodeling of transcriptional networks to adapt to metabolic changes. In-
creased purines and pyrimidines may support anabolic metabolism for RNA and protein 
synthesis; 3-hydroxybutyrate (3-HB), a major energy substitute during fasting, is also 
known as a histone deacetylase inhibitor [79], while 2-oxoglutarate activates 2-oxoglu-
tarate oxygenase, functioning in demethylation of histones and nucleic acids, and desta-
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of human whole blood. Various antioxidative metabolit s are included in the list of aging and fasting
markers. In addition to known energy substitutions, unexpected aspects of fasting (antioxidants,
mitochondrial activation, and signal reprogramming) were revealed. In response to 58-h fasting,
44 human metabolites increased, revealing remarkable metabolic activation. Metabolites increased
during fasting did not overlap with the compounds increased in elderly, except pantothenate. Please
notice that four metabolites decreased in elderly (OA, carnosine, leucine, and isoleucine) were
increased during fasting, indicating the possible anti-aging effect of fasting. BCAA; branched chain
amino acid, ET; ergothioneine, 1,5-AG; 1,5-anhydroglucitol (1,5-AG), OA; ophthalmic acid, PPP;
pentose phosphate pathway.
Third, whole blood metabolomics identified purines and pyrimidines (GTP, CTP, ADP,
IMP, cytidine, and adenine) and some signal-modulating metabolites (3-hydroxybutyrate
and 2-oxoglutarate) as fasting markers [54]. It is conceivable that fasting provokes global
remodeling of transcriptional networks to adapt to metabolic changes. Increased purines
and pyrimidines may support anabolic metabolism for RNA and protein synthesis; 3-
hydroxybutyrate (3-HB), a major energy substitute during fasting, is also known as a
histone deacetylase inhibitor [79], while 2-oxoglutarate activates 2-oxoglutarate oxygenase,
functi ning in demethylat on of histones and ucleic acids, destabilization of tran-
scripti al actors [80]. Fasting may genetically or epi modify transcriptional
networks via such metabol te . [79,80].
I t r sti l , f r etabolites that increase during fasting (carnosine, OA, leucine,
and isoleucine) overlap ith the decreased metabolites in elderly (Table 1 and Figure 2).
It is possible that fasting ay exert anti-aging or rejuvenile effect through upregulation of
these aging metabolites.
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5. Whole Blood Metabolome for Diseases of Aging
5.1. Metabolomic Study of Frailty
Most aging-related diseases are increasing in our globally aging society, including
lifestyle diseases (hypertension, diabetes, obesity, osteoporosis, atherosclerosis, etc.), de-
mentia, cancer, and others. Among other factors, the severity of frailty is most closely
correlated with health risks of advanced age [81]. Frailty is a vulnerability to stressors, due
to the declining physiological capacity of organs as a result of aging [82,83]. Because it
results from age-related deterioration of multiple organ systems, frailty displays complex
features, including cognitive dysfunction, hypomobility, and impaired daily activity.
Frailty is currently defined by three major diagnostic tools [84]. The Fried Cardiovas-
cular Health Study Index (CHS) is useful to detect physical frailty [82], while the Rockwood
Frailty Index covers its multimorbidity [85]. In contrast, the Edmonton Frailty Scale (EFS)
or Tilburg Frailty Indicator, efficiently evaluates both physical and psychosocial aspects of
frailty [86,87].
Four recent studies reported the metabolomic analysis of blood from frail elderly
subjects [88–91]. However, these reports drew divergent, non-overlapping conclusions,
stemming from different experimental designs. For example, the former two reports
applied the Fried CHS index as a diagnostic tool, which lacks cognitive assessment, while
the latter two utilized the Rockwood Frailty index. Since these studies were based on serum
samples, we performed whole blood metabolomics for frailty. Our study was designed
to cover multiple domains of frailty, by applying the EFS, the Japanese version of the
Montreal Cognitive Assessment (MoCA-J) [92,93] and the Timed Up & Go Test (TUG) [94]
as diagnostic tools [86], because the EFS is recognized as a valid and reliable measurement
tool for identification of frailty [95] and is widely recommended in clinical guidelines [84].
Using the EFS as a guide, our study identified 15 blood metabolites involved in
antioxidation, cognition, and mobility as frailty markers (Figure 3) [56], while studies based
on the Fried CHS reported blood metabolites related mainly to physical or sarcopenic
frailty [89].
5.2. Frailty Markers for Anti-Oxidation, Cognition, and Mobility
First, among 15 frailty markers, seven compounds that decreased in frailty are as-
sociated with antioxidative defense: Acetyl-carnosine, ergothioneine (ET), S-methyl-ET,
trimethyl-histidine, OA, 2-ketobutyrate, and urate (Figure 3). Trimethyl-histidine and
S-methyl-ET are involved in ET synthesis (20); 2-ketobutyrate is a precursor of OA. Thus,
the ergothioneine and OA pathways are greatly affected in frailty. Second, we observed
that five amino acids (methionine, proline, tryptophan, isoleucine, and leucine) decreased
significantly in frail subjects. Among these five amino acids, methionine, proline, and
tryptophan, have been reported as radical scavengers in vitro [96–99]. Thus, our whole
blood metabolome for frailty revealed antioxidant enrichment in cellular components.
Consistently, recent findings of longitudinal studies support our notion that diminished
antioxidative defenses are heavily involved in pathogenesis of frailty [100]. It is noteworthy
that most cognitive markers and some hypomobility markers overlap with frailty mark-
ers, supporting the notion that frailty is an integrated spectrum of age-related disorders
(Figure 3). On the other hand, only acetyl-carnosine overlapped in aging and cognitive
markers, indicating the gap between physiological and pathological aging in cognition.
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Figure 3. Metabolites for aging, frailty, and cognitive impairment. Various antioxidative metabolites
are included in the list of aging, frailty, and cognitive markers. Among fifteen frailty markers, eleven
anti-oxidative metabolites are decreased, indicating the involvement of antioxidative defense in the
pathogenesis of frailty. Among fourteen aging markers, five metabolites (acetyl-carnosine, 1,5-AG,
OA, leucine, and isoleucine) overlapped with frailty markers. Among six cognitive markers, five
compounds (acetyl-carnosine, 1,5-AG, OA, UDP-glucuronate and creatine) overlapped with frailty
markers, reflecting the cognitive aspects of frailty. Thus, cognitive markers are much involved in
frailty markers, while one compound (acetyl-carnosine) are listed as overlapping both in aging and
cognitive markers. Collectively, overlapping, but distinct markers for aging, frailty, and cognition are
identified by non-targeted, whole blood metabolomics.
6. Summary
Interestingly, metabolites affected in frailty largely overlap with metabolites that
decrease during aging (acetyl-carnosine, OA, 1,5-AG, isoleucine, and leucine) and com-
pounds that increase during fasting (2-ketobutyrate, OA, isoleucine, leucine, urate and
ET), indicating an intriguing metabolic link between frailty and human aging. Various
antioxidative metabolites are conspicuously included among frailty and aging markers,
suggesting that one of the key stressors to which frail elderly are vulnerable is oxidative
stress. In this context, increased oxidative defense during fasting may effectively moderate
aging or aging-relevant disorders.
Diversity of aging has a significant impact not only on clinical and basic research, but
also on national economies, and facilitates structural changes in entire societies. The answer
to the fundamental question, “What is aging?” is not yet fully known. Accumulating
evidence suggests that defining “aging” only on the basis of chronological age does not
explain the entire situation. Interestingly, some of the metabolites described in this review
are known to interact with the signal molecules (Figure 1). NAD+, decreased in elderly,
activates Sirtuin, while citrulline, accumulated in elderly, stimulates TOR kinase; 3-HB
inhibits histone deacetylases, followed by FOXO activation. Thus, metabolites might affect
aging or aging-related diseases by modulating signal modules [79,101–104]. As one hint
of human aging research, results of whole blood metabolomics help to better understand
biological age, especially given the variable nature of aging.
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